Article: Nicotinamide Riboside Protects Against Liver Fibrosis: Preclinical Findings

PrevNext
Neurological Health Orphan Disease Preclinical

Nicotinamide Riboside Protects Against Liver Fibrosis: Preclinical Findings

Synopsis

Nicotinamide riboside (NR) boosts NAD+ levels and offers protective effects in various diseases, but its role in liver fibrosis is unclear. This study tested NR’s ability to protect against liver fibrosis in mice and liver cells. Mice with liver fibrosis induced by CCl4 were treated with NR, which prevented and even reversed fibrosis. In liver cells, NR stopped the cells from activating and causing damage by activating Sirt1 and lowering certain protein modifications. When Sirt1 was blocked, NR’s protective effect was reduced. These results show that NR protects against liver fibrosis by suppressing harmful cell activation, highlighting NR’s potential as a therapeutic agent for liver fibrosis.

Journal

Life Sciences

Share

Read more

Liver Health

Nicotinamide Riboside Kinases Mediate NMN and NR Metabolism in Muscle Cells: Preclinical Findings

Synopsis Increasing NAD+ levels may help protect muscles from age-related decline. This study examined how skeletal muscle cells make NAD+ from precursors nicotinamide mononucleotide (NMN) and nic...

Read more
Muscle Health

Nicotinamide Riboside Reduces Alcohol-Related Liver Damage: Preclinical Findings

Synopsis Alcohol causes liver damage by lowering the activity of SIRT1, a protein that regulates fat metabolism and mitochondrial function. Giving mice nicotinamide riboside (NR), an NAD+ precurso...

Read more